Sensus Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023
January 23, 2024 at 08:00 am EST
Share
Sensus Healthcare, Inc. provided revenue guidance for the fourth quarter and full year ended December 31, 2023. for the quarter, the company expects to report revenue of more than $12 million.
For the year, the company expects revenue expected to exceed $23 million.
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100+ and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100+ offer remote diagnostics solutions, including operation tracking.